MELAS Syndrome Overview
Learn About MELAS Syndrome
Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) is a condition that affects many of the body's systems, particularly the brain and nervous system (encephalo-) and muscles (myopathy). The signs and symptoms of this disorder most often appear in childhood following a period of normal development, although they can begin at any age. Early symptoms may include muscle weakness and pain, recurrent headaches, loss of appetite, vomiting, and seizures. Most affected individuals experience stroke-like episodes beginning before age 40. These episodes often involve temporary muscle weakness on one side of the body (hemiparesis), altered consciousness, vision abnormalities, seizures, and severe headaches resembling migraines. Repeated stroke-like episodes can progressively damage the brain, leading to vision loss, problems with movement, and a loss of intellectual function (dementia).
MELAS can result from mutations in one of several genes, including MT-ND1, MT-ND5, MT-TH, MT-TL1, and MT-TV. These genes are found in the DNA of cellular structures called mitochondria, which convert the energy from food into a form that cells can use. Although most DNA is packaged in chromosomes within the nucleus, mitochondria also have a small amount of their own DNA, known as mitochondrial DNA or mtDNA.
The exact incidence of MELAS is unknown. It is one of the more common conditions in a group known as mitochondrial diseases. Together, mitochondrial diseases occur in about 1 in 4,000 people.
This condition is inherited in a mitochondrial pattern, which is also known as maternal inheritance. This pattern of inheritance applies to genes contained in mtDNA. Because egg cells, but not sperm cells, contribute mitochondria to the developing embryo, children can only inherit disorders resulting from mtDNA mutations from their mother. These disorders can appear in every generation of a family and can affect both males and females, but fathers do not pass traits associated with changes in mtDNA to their children.
The General Hospital Corporation
Amel Karaa is a Medical Genetics provider in Boston, Massachusetts. Dr. Karaa and is rated as a Distinguished provider by MediFind in the treatment of MELAS Syndrome. Her top areas of expertise are MELAS Syndrome, Fabry Disease, Multiple Sulfatase Deficiency, and Megalencephalic Leukoencephalopathy with Subcortical Cysts. Dr. Karaa is currently accepting new patients.
Mainehealth
Roople Unia is a Neurologist in Brunswick, Maine. Dr. Unia and is rated as a Distinguished provider by MediFind in the treatment of MELAS Syndrome. Her top areas of expertise are MELAS Syndrome, Epilepsy, Migraine, and Memory Loss. Dr. Unia is currently accepting new patients.
Mam Ibraheem is a Neurologist in Lowell, Massachusetts. Dr. Ibraheem and is rated as an Advanced provider by MediFind in the treatment of MELAS Syndrome. His top areas of expertise are MELAS Syndrome, Generalized Tonic-Clonic Seizure, Neurotoxicity Syndromes, and Seizures. Dr. Ibraheem is currently accepting new patients.
Summary: PRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs. placebo when administered daily for 12 weeks in participants with genetically and phenotypically defined MELAS.
Summary: Carriers of the m.3242A\>G mutation often have clinical symptoms which can include migraines, seizures, strokes, hearing loss, balance issues, gastrointestinal issues, and many other symptoms. The investigators would like to learn more about these disorders and have designed a Natural History Study to monitor these conditions over time so that physicians and scientists can not only understand the ...
Published Date: December 01, 2013
Published By: National Institutes of Health